NO975887L - Sulfonamidsubstituerte forbindelser, fremgangsmÕte for deres fremstilling, deres anvendelse som et medikament eller diagnostikum, og farmas°ytiske sammensetninger inneholdende dem - Google Patents
Sulfonamidsubstituerte forbindelser, fremgangsmÕte for deres fremstilling, deres anvendelse som et medikament eller diagnostikum, og farmas°ytiske sammensetninger inneholdende demInfo
- Publication number
- NO975887L NO975887L NO975887A NO975887A NO975887L NO 975887 L NO975887 L NO 975887L NO 975887 A NO975887 A NO 975887A NO 975887 A NO975887 A NO 975887A NO 975887 L NO975887 L NO 975887L
- Authority
- NO
- Norway
- Prior art keywords
- processes
- preparation
- stands
- carbon atoms
- sulfonamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 101100168606 Caenorhabditis elegans crh-2 gene Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/16—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1996152213 DE19652213A1 (de) | 1996-12-16 | 1996-12-16 | Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE1997130326 DE19730326A1 (de) | 1997-07-15 | 1997-07-15 | Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO975887D0 NO975887D0 (no) | 1997-12-15 |
| NO975887L true NO975887L (no) | 1998-06-17 |
Family
ID=26032247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO975887A NO975887L (no) | 1996-12-16 | 1997-12-15 | Sulfonamidsubstituerte forbindelser, fremgangsmÕte for deres fremstilling, deres anvendelse som et medikament eller diagnostikum, og farmas°ytiske sammensetninger inneholdende dem |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5856338A (hu) |
| EP (1) | EP0847996B1 (hu) |
| JP (1) | JP4317601B2 (hu) |
| KR (1) | KR19980064151A (hu) |
| CN (1) | CN1185435A (hu) |
| AT (1) | ATE234821T1 (hu) |
| AU (1) | AU725699B2 (hu) |
| BR (1) | BR9706142A (hu) |
| CA (1) | CA2224885A1 (hu) |
| CZ (1) | CZ403997A3 (hu) |
| DE (1) | DE59709560D1 (hu) |
| DK (1) | DK0847996T3 (hu) |
| ES (1) | ES2195071T3 (hu) |
| HR (1) | HRP970684A2 (hu) |
| HU (1) | HUP9702475A3 (hu) |
| ID (1) | ID19152A (hu) |
| IL (1) | IL122576A0 (hu) |
| NO (1) | NO975887L (hu) |
| NZ (1) | NZ329200A (hu) |
| PL (1) | PL323809A1 (hu) |
| PT (1) | PT847996E (hu) |
| SI (1) | SI0847996T1 (hu) |
| SK (1) | SK171797A3 (hu) |
| TR (1) | TR199701605A2 (hu) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711220D0 (en) * | 1997-05-30 | 1997-07-23 | Isis Innovation | Antiarrhythmic agents |
| EP1276893A4 (en) | 2000-04-14 | 2005-05-04 | Univ Vanderbilt | NUCLEIC ACIDS AND PYRIFICATED POYPEPTIDES AND ISOLES COTRANSPORTORS OF POTASSIUM CHLORIDE |
| TWI349666B (en) * | 2004-03-12 | 2011-10-01 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivatives |
| CN113402476B (zh) * | 2021-06-21 | 2022-04-19 | 广东湛江海洋医药研究院 | 一种亚胺噁嗪衍生物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3737195A1 (de) * | 1987-11-03 | 1989-05-18 | Bayer Ag | Chromanderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| GB8808069D0 (en) * | 1988-04-07 | 1988-05-11 | Fujisawa Pharmaceutical Co | Benzopyran derivatives & processes for preparation thereof |
| FR2639349B1 (fr) * | 1988-11-23 | 1991-02-22 | Sanofi Sa | Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant |
| US5104890A (en) * | 1989-03-28 | 1992-04-14 | Fujisawa Pharmaceutical Company, Ltd. | Benzopyran derivatives and processes for preparation thereof |
| TW258735B (hu) * | 1992-08-17 | 1995-10-01 | Chugai Pharmaceutical Co Ltd | |
| CN1204134C (zh) * | 1996-05-15 | 2005-06-01 | 赫彻斯特股份公司 | 氨磺酰－取代的苯并二氢吡喃,其制法,作为药物或诊断剂的应用及含有它的药物 |
-
1997
- 1997-11-18 NZ NZ329200A patent/NZ329200A/xx unknown
- 1997-12-05 AT AT97121437T patent/ATE234821T1/de not_active IP Right Cessation
- 1997-12-05 SI SI9730534T patent/SI0847996T1/xx unknown
- 1997-12-05 EP EP97121437A patent/EP0847996B1/de not_active Expired - Lifetime
- 1997-12-05 ES ES97121437T patent/ES2195071T3/es not_active Expired - Lifetime
- 1997-12-05 DK DK97121437T patent/DK0847996T3/da active
- 1997-12-05 DE DE59709560T patent/DE59709560D1/de not_active Expired - Lifetime
- 1997-12-05 PT PT97121437T patent/PT847996E/pt unknown
- 1997-12-11 ID IDP973864A patent/ID19152A/id unknown
- 1997-12-12 TR TR97/01605A patent/TR199701605A2/xx unknown
- 1997-12-12 IL IL12257697A patent/IL122576A0/xx unknown
- 1997-12-12 SK SK1717-97A patent/SK171797A3/sk unknown
- 1997-12-15 US US08/990,455 patent/US5856338A/en not_active Expired - Lifetime
- 1997-12-15 HU HU9702475A patent/HUP9702475A3/hu unknown
- 1997-12-15 CN CN97125504A patent/CN1185435A/zh active Pending
- 1997-12-15 NO NO975887A patent/NO975887L/no not_active Application Discontinuation
- 1997-12-15 HR HR19730326.9A patent/HRP970684A2/hr not_active Application Discontinuation
- 1997-12-15 AU AU48373/97A patent/AU725699B2/en not_active Ceased
- 1997-12-15 JP JP34546997A patent/JP4317601B2/ja not_active Expired - Fee Related
- 1997-12-15 BR BR9706142A patent/BR9706142A/pt not_active Application Discontinuation
- 1997-12-15 CZ CZ974039A patent/CZ403997A3/cs unknown
- 1997-12-16 PL PL97323809A patent/PL323809A1/xx unknown
- 1997-12-16 KR KR1019970068995A patent/KR19980064151A/ko not_active Application Discontinuation
- 1997-12-16 CA CA002224885A patent/CA2224885A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ329200A (en) | 1999-05-28 |
| JPH10182610A (ja) | 1998-07-07 |
| EP0847996B1 (de) | 2003-03-19 |
| JP4317601B2 (ja) | 2009-08-19 |
| PT847996E (pt) | 2003-07-31 |
| NO975887D0 (no) | 1997-12-15 |
| PL323809A1 (en) | 1998-06-22 |
| TR199701605A2 (xx) | 1998-07-21 |
| CN1185435A (zh) | 1998-06-24 |
| CA2224885A1 (en) | 1998-06-16 |
| DK0847996T3 (da) | 2003-06-30 |
| ATE234821T1 (de) | 2003-04-15 |
| HUP9702475A2 (hu) | 1999-06-28 |
| KR19980064151A (ko) | 1998-10-07 |
| US5856338A (en) | 1999-01-05 |
| AU725699B2 (en) | 2000-10-19 |
| SI0847996T1 (en) | 2003-08-31 |
| IL122576A0 (en) | 1998-06-15 |
| CZ403997A3 (cs) | 1998-07-15 |
| ES2195071T3 (es) | 2003-12-01 |
| BR9706142A (pt) | 1999-05-18 |
| DE59709560D1 (de) | 2003-04-24 |
| HU9702475D0 (en) | 1998-03-02 |
| SK171797A3 (en) | 1998-07-08 |
| HUP9702475A3 (en) | 2000-01-28 |
| EP0847996A1 (de) | 1998-06-17 |
| MX9710126A (es) | 1998-07-31 |
| AU4837397A (en) | 1998-06-18 |
| ID19152A (id) | 1998-06-18 |
| HRP970684A2 (en) | 1998-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP43008A (en) | Indole-2-carboxamides as factor xa inhibitors | |
| EG20001A (en) | Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| SE0104340D0 (sv) | New compounds | |
| BR0211228A (pt) | Composto, composição farmacêutica e seus usos | |
| CA2223403A1 (en) | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds | |
| HUP0401192A2 (hu) | Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására | |
| HUP9600448A2 (hu) | Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk | |
| IL154536A0 (en) | Immunoregulatory compounds and derivatives and methods of treating diseases therewith | |
| JPH06500078A (ja) | Ｔｎｆ抑制剤 | |
| MY128014A (en) | Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors | |
| ES2036926A1 (es) | "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina". | |
| CA2274686A1 (en) | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| US20030050329A1 (en) | Synergistic combination comprising roflumilast and a PDE-3 inhibitor | |
| NO975887L (no) | Sulfonamidsubstituerte forbindelser, fremgangsmÕte for deres fremstilling, deres anvendelse som et medikament eller diagnostikum, og farmas°ytiske sammensetninger inneholdende dem | |
| WO1989005637A1 (en) | Improving toxicity profiles in chemotherapy | |
| SE9901572D0 (sv) | New compounds | |
| CA1327163C (en) | Anxiolytically active piperazine derivatives | |
| SE0201837D0 (sv) | Chemical compounds | |
| EP0664127B1 (en) | Pharmaceutical compositions containing isoquinoline derivatives | |
| MY118262A (en) | Sulfonamide-substituted benzopyran derivatives, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them | |
| ES2378374T3 (es) | Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial | |
| Spina et al. | The role of platelet activating factor in allergic inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |